First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, X. Cynthia et al.|New England Journal of Medicine|2025Cited by 106
Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatmentNicholas C. Turner, François‐Clément Bidard, Cynthia Huang Bartlett et al.|Future Oncology|2023Cited by 78